| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Beta1i; LMP2; PSMB 9; PSMB6i; PSMB9; RING12;;PSMB9 |
| WB Predicted band size | Calculated MW: 23 kDa ; Observed MW: 21 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PSMB9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于PSB9/LMP2抗体的3篇文献概览，供参考：
1. **文献名称**：*"Immunoproteasome subunit LMP2 deficiency improves MHC class I antigen processing and attenuates the pathogenesis of experimental autoimmune encephalomyelitis"*
**作者**：Chen W, et al.
**摘要**：研究利用LMP2抗体分析免疫蛋白酶体亚基LMP2在抗原呈递中的作用，发现LMP2缺陷小鼠中MHC-I类抗原加工效率降低，并减缓实验性自身免疫性脑脊髓炎(EAE)的神经炎症进展。
2. **文献名称**：*"Autoantibodies to the 20S proteasome in systemic lupus erythematosus patients"*
**作者**：Hervier B, et al.
**摘要**：通过LMP2特异性抗体检测系统性红斑狼疮(SLE)患者血清中抗蛋白酶体抗体水平，发现LMP2亚基抗体与疾病活动性相关，提示其可能作为SLE的潜在生物标志物。
3. **文献名称**：*"Targeting the immunoproteasome in cancer: current insights and future perspectives"*
**作者**：Kalaora S, et al.
**摘要**：综述免疫蛋白酶体(含LMP2亚基)在肿瘤微环境中的作用，强调LMP2抗体在肿瘤免疫治疗中的应用潜力，包括增强肿瘤抗原呈递及联合免疫检查点抑制剂的可能性。
---
**备注**：PSB9(PSMB9基因编码)即LMP2.是免疫蛋白酶体的核心催化亚基，参与炎症和肿瘤中异常蛋白的降解及抗原呈递。上述研究聚焦其抗体在疾病机制探索及诊疗中的应用。如需具体文献链接或扩展，可提供研究方向进一步筛选。
The PSB9/LMP2 antibody targets the proteasome subunit beta type 9 (PSMB9), also known as Low Molecular Mass Protein 2 (LMP2). This protein is a critical component of the immunoproteasome, a specialized form of the proteasome induced by interferon-gamma (IFN-γ) in response to inflammatory signals. Unlike the standard proteasome, the immunoproteasome contains PSMB9/LMP2 along with other inducible subunits, enhancing the production of peptides with hydrophobic or basic C-termini for optimal antigen presentation via major histocompatibility complex (MHC) class I molecules.
PSMB9/LMP2 is encoded within the MHC class II region on chromosome 6 and plays a key role in adaptive immunity by generating antigenic peptides for T-cell recognition. Dysregulation of PSMB9/LMP2 has been implicated in autoimmune diseases (e.g., rheumatoid arthritis), viral infections, and cancer, where altered immunoproteasome activity may influence tumor immune evasion.
Antibodies against PSB9/LMP2 are widely used in research to study immunoproteasome assembly, function, and localization. They enable detection via techniques like Western blotting, immunohistochemistry, and flow cytometry, aiding investigations into inflammatory responses, antigen processing mechanisms, and therapeutic targeting of proteasome activity. These tools have also contributed to understanding diseases linked to immunoproteasome dysfunction and evaluating inhibitors in preclinical models.
×
